Stelios Tzellos Highlights Verified Contributions to Oncology Forecasting and Evidence-Based Strategy

London, UK, 11 Dec 2025, ZEX PR WIRE, Stelios Tzellos, Ph.D., is a UK-based molecular biologist and pharmaceutical analyst whose work has contributed to the understanding of both viral gene regulation and oncology market dynamics. With academic roots in biochemistry and molecular biology, and an industry career spanning consulting and analytics roles, Dr. Tzellos has become known for his involvement in evidence-driven oncology strategy.

After earning his Bachelor's and Master's degrees in Biochemistry at Imperial College London, he completed a doctorate in Molecular Biology at the same institution. His Ph.D. research explored the differential regulatory effects of EBV EBNA-2 proteins on host and viral genes. The focus of this work was on understanding how a single amino acid substitution (S442D) in the EBNA-2 protein alters its ability to induce genes like CXCR7, contributing to the growth-promoting phenotype seen in Type 1 EBV.

Dr. Tzellos' first-author publication, as well as co-authored papers from this research, are indexed in PubMed and remain relevant to those studying EBV biology, B-cell transformation, and transcriptional regulation.

Following completion of his Ph.D., Dr. Tzellos moved into pharmaceutical market analysis, beginning at GlobalData. There, as an Oncology and Haematology Analyst, he participated in market forecasting and treatment landscape evaluations. He was quoted in a 2014 industry report focused on the projected growth of the Hodgkin's lymphoma treatment market. His comments highlighted the significance of Adcetris in reshaping access for premium-priced therapies targeting R/R disease subsets:

"Adcetris currently accounts for 77.6% of the total market and is predicted to make up 82.4% of sales by the end of the forecast period. Premium-priced pipeline therapies that target the R/R Hodgkin's lymphoma population will find it easier to penetrate the market, as Adcetris has already opened the door for expensive therapeutics in this setting."

That statement has since been cited in discussions about market entry barriers, payer dynamics, and the economics of targeted cancer therapies.

Dr. Tzellos later worked at IQVIA in a role that continued to focus on pharmaceutical analytics. His focus has remained within oncology and pharmaceutical strategy. He currently holds a role at AstraZeneca in the UK.

While not all of his industry work is in the public domain, his academic and consulting background has shaped a clear professional profile centered on evidence-based strategy and real-world data application. Dr. Tzellos' public writing includes personal blog posts and medium articles covering the role of science in forecasting, the rise of real-world evidence in oncology, and transitions from academic research to commercial roles.

His interests extend beyond professional analytics. Dr. Tzellos is married with two children and is an active follower of sports such as football, basketball, and Formula 1. He enjoys music, regularly attends live performances, and takes on hands-on projects around the house. These personal interests provide balance to his data-heavy professional work and illustrate the range of his day-to-day experience.

By grounding strategic insights in scientific training and verified industry contributions, Stelios Tzellos represents a model of evidence-based thinking in pharmaceutical analytics.

This release was published on openPR.